SMA2 is caused by pathogenic variants in the SMN1 gene, which lead to degeneration and irreversible loss of anterior horn cells in the spinal cord and motor neurons in brain stem nuclei. The condition is inherited in an autosomal recessive manner, meaning that disease manifestation generally requires pathogenic variants affecting both copies of the SMN1 gene. The loss of these lower motor neurons disrupts signaling to skeletal muscle, producing the progressive weakness, atrophy, and hypotonia characteristic of the disorder. Per expert review, the SMN2 gene, a paralog of SMN1, can modify disease severity, and its copy number is a factor considered in molecular evaluation of SMA.

Diagnostic approaches to SMA, as outlined in consensus documents referenced per clinical guidelines, describe multiple presenting scenarios, including identification through abnormal newborn screening results. Newborn screening for SMA is primarily based on real-time PCR methods that detect the common SMN1 deletion and may also assess SMN2 copy number using dried blood spot samples. Beyond newborn screening, suggestive clinical findings—such as proximal muscle weakness, hypotonia, EMG abnormalities, and tongue fasciculations—prompt further genetic evaluation. Molecular genetic testing confirming biallelic pathogenic variants or deletions in SMN1 establishes the diagnosis. Per expert review, genetic confirmation of SMA has also clarified that the disease exists along a broad clinical spectrum rather than in fully distinct categories, which is relevant when interpreting diagnostic findings alongside clinical presentation.

There is currently no cure for SMA. Per expert review, three targeted therapies addressing the underlying molecular mechanism of SMA are available and have demonstrated a positive effect on disease progression. These include nusinersen (Spinraza), onasemnogene abeparvovec-xioi (Zolgensma), and risdiplam (Evrysdi), all of which are approved treatments associated with this condition. In GeneReviews terminology, a targeted therapy is one addressing the specific underlying disease mechanism, regardless of the degree of efficacy for any particular manifestation, and would not otherwise be considered without knowledge of the underlying genetic cause. Beyond these targeted approaches, management of SMA has historically included supportive measures addressing respiratory, nutritional, and musculoskeletal manifestations, consistent with the multisystem impact of motor neuron loss. Orphan drug designations have also been granted for other agents, including pegylated insulin-like growth factor 1 (PEG-IGF1), which holds a designation status, and branaplam, for which the designation was withdrawn; designation status does not indicate regulatory approval.

Per clinical guidelines, the exact prevalence and long-term natural history of SMA have been difficult to establish with precision, partly due to limitations in older studies conducted prior to the availability of genetic confirmation. Historical estimates may have underrepresented more severe phenotypes because of shortened lifespan in those populations. The introduction of targeted treatment options has altered the natural history of SMA phenotypes, including type II, changing the trajectory of disease progression compared to historical descriptions. Per expert review, this shift has also blurred the boundaries between historically defined SMA subtypes, complicating strict prognostic categorization based solely on type designation.

Seven certified active trial records are associated with this condition, spanning phases including non-applicable, Phase 1, Phase 2, and Phase 3 designations. These trials reflect ongoing clinical investigation into treatment approaches for spinal muscular atrophy. Additionally, orphan drug designations have been granted for agents including pegylated insulin-like growth factor 1 (PEG-IGF1), which remains in designated status, and branaplam, for which the orphan designation was withdrawn. These designations reflect regulatory recognition of potential therapeutic interest but do not constitute approval for clinical use.